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Abstract
Background: The cis-acting promoter element responsible for epigenetic silencing of retinoic acid receptor responder 1
(RARRES1) by methylation is unclear. Likewise, how aberrant methylation interplays effectors and thus affects breast
neoplastic features remains largely unknown.
Methodology/Principal Findings: We first compared methylation occurring at the sequences (2664,+420) flanking the
RARRES1 promoter in primary breast carcinomas to that in adjacent benign tissues. Surprisingly, tumor cores displayed
significantly elevated methylation occurring solely at the upstream region (2664,286), while the downstream element
(285,+420) proximal to the transcriptional start site (+1) remained largely unchanged. Yet, hypermethylation at the former
did not result in appreciable silencing effect. In contrast, the proximal sequence displayed full promoter activity and
methylation of which remarkably silenced RARRES1 transcription. This phenomenon was recapitulated in breast cancer cell
lines, in which methylation at the proximal region strikingly coincided with downregulation. We also discovered that CTCF
occupancy was enriched at the unmethylayed promoter bound with transcription-active histone markings. Furthermore,
knocking-down CTCF expression hampered RARRES1 expression, suggesting CTCF positively regulated RARRES1
transcription presumably by binding to unmethylated promoter poised at transcription-ready state. Moreover, RARRES1
restoration not only impeded cell invasion but also promoted death induced by chemotherapeutic agents, denoting its
tumor suppressive effect. Its role of attenuating invasion agreed with data generated from clinical specimens revealing that
RARRES1 was generally downregulated in metastatic lymph nodes compared to the tumor cores.
Conclusion/Significance: This report delineated silencing of RARRES1 by hypermethylation is occurring at a proximal
promoter element and is associated with a loss of binding to CTCF, an activator for RARRES1 expression. We also revealed
the tumor suppressive roles exerted by RARRES1 in part by promoting breast epithelial cell death and by impeding cell
invasion that is an important property for metastatic spread.
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Introduction
Retinoic acid receptor responder (Tazarotene-induced gene) 1
(RARRES1, alias TIG1), initially identified as a downstream target
of retinoic acid signaling [1], was demonstrated to be inactivated
in primary tumors and cell lines of human cancers. Other than
inhibiting tumorigenesis and hampering invasive properties of
prostate cancer [2], increasing lines of evidence have indicated
RARRES1 as an important tumor suppressor gene by regulating
versatile cellular processes like cell proliferation, differentiation,
and survival [3–5]. For instance, RARRES1 restoration in
leukemic K562 cells cooperated with all-trans retinoic acid to
induce cell apoptosis [3]. Likewise, RARRES1 impeded cell
proliferation and invasive features of nasopharyngeal carcinoma
cells mediated by Epstein-Barr virus [4]. Furthermore, RARRES1
modulated the differentiation of subcutaneous adipose tissue-
derived mesenchymal stem cell [5]. However, the tumor
suppressive effect of RARRES1 on breast carcinomas has not
been proven so far, but began to be illustrated in current report.
To date, promoter hypermethylation was shown to downreg-
ulate RARRES1 expression in a variety of cancers [3,6–8]. In
support of this notion, our group recently discovered that
hypermethylation at the RARRES1 promoter flanking sequences
can be induced by an exposure to breast cancer-associated
fibroblasts [9]. Yet, the past reports haven’t precisely defined the
crucial cis-element responsible for epigenetic silencing of
RARRES1 by methylation nor how various DNA segments interact
with each other and with transcription factors. This study,
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resolution, namely MassARRAY, for quantifying the levels of
methylation occurring at either individual or at the clusters of
CpG dinucleotides [10]. We assessed the levels of methylation at
sequences flanking RARRES1 promoter in 18 pairs of breast tumor
cores plus adjacent benign tissues as well as in breast cancer cell
lines and have discovered methylation at two regions can exert
strikingly distinct epigenetic outcomes. While distal sequences
(2664,286) displayed negligible promoter activity and methyl-
ation of which conferred unnoticeable silencing effect, the
proximal region flanking sequences 285,+420 harbored remark-
able promoter function and methylation of which downregulated
gene expression. Perhaps, methylation at the former motif
preludes a methylation spread into the latter segment where
epigenetic silencing effect virtually takes place.
On the other hand, CCCTC-binding factor (CTCF) is a highly
conserved zinc finger protein with diverse functions involving not
only transcriptional regulation, but also DNA methylation as well
as organization of global chromosomal architecture through
boundary/insulator formation [11–13]. CTCF contains a central
DNA-binding domain consisting of 11 zinc fingers that confers its
ability to bind to a wide range of DNA sequences [11,12]. Inferred
by data generated from chromatin immunoprecipitation (ChIP)
coupled by microarray chip arrays (know as ChIP-chip), a putative
CTCF binding motif was predicted in sequences flanking
RARRES1 transcriptional start site (TSS) [14] (Figure S1). We
therefore investigated whether binding to CTCF was able to
regulate RARRES1 transcription experimentally. Our data re-
vealed that CTCF occupancy was not only enriched at the
unmethylated RARRES1 promoter harboring transcription-active
histone markings, but also positively correlated with RARRES1
expression such that knocking down CTCF was able to suppress
RARRES1 transcription. Together, this study redefined an
important promoter element responsible for epigenetic silencing
of RARRES1 by DNA methylation and by impeding the binding to
CTCF. Moreover, the roles RARRES1 plays in breast neoplasm
remain largely undiscovered to date. However, this report
demonstrated that RARRES1 acts as a breast tumor suppressor
in part by enhancing cell death after chemotherapeutic agent
treatments and by impeding metastatic spread. Silencing of
RARRES1by methylation and by a loss of CTCF binding possibly
augmented neoplastic properties associated with advanced breast
carcinomas.
Materials and Methods
Patients’ Specimens and Cell Lines
Fresh breast tumors and the matched adjacent benign tissues
were procured from the Department of Pathology of the Ohio
State University (OSU), in compliance with the institutional
review board of OSU with an approved protocol number
2008C0048. Patients’ clinical information can be found in the
Table S1. Immediately after procurement, tissues were macro-
dissected by our qualified pathologist and flash frozen at 280uC
until DNA and RNA extraction.
Normal human mammary epithelial cells derived from three
different women (designated as HMEC-1, -2 and -3) were
purchased from Lonza and from ScienceCell Research Labora-
tories (Carlsbad, CA). Cells were cultured in mammary epithelial
growth medium (MEGM) (Lonza). All breast cancer cell lines used
in this study were generous gifts from Dr. Max S. Wicha [15].
MCF10A cells were grown in DMEM/F12 medium supplemented
with 5% horse serum, Epidermal Growth Factor (EGF; 20 ng/ml),
insulin (10 mg/ml), hydrocortisone (500 ng/ml), and cholera toxin
(100 ng/ml). BrCa-MZ-01 and SK-BR-7 cells were proliferated in
RPMI1640 plus 10% Fetal Bovine Serum (FBS) whereas SUM149
and SUM159 cells were propagated in F12 medium with 5% FBS
and hydrocortisone (1 mg/ml). For inducing RARRES1 expres-
sion in SUM159 cells, tetracycline (Tet)-free FBS was employed in
lieu of regular FBS. Unless specified elsewhere, the remaining cells
were grown in DMEM with 10% FBS. Moreover, antibiotic-
antimycotic (Invitrogen) was routinely added to all culture media
for preventing microbial contamination.
Quantification of DNA Methylation by MassARRAY
Technology
To finely quantify the levels of methylation occurring at the
sequences flanking RARRES1 promoter, a high-throughput system
namely MassARRAY platform (Sequenom) was utilized as
described previously [9].
Retroviral Vectors and Infections
Retroviral plasmids, pRetroX-Tet-On Advanced and pRetroX-
Tight-Pur vectors, were purchased from Clontech. In principle, to
generate recombinant retroviruses, plasmids were respectively
transfected into packaging cells namely Phoenix
TM Ampho
(Orbigen, Inc.; San Diego, CA) mediated by calcium phosphate.
24 hours later, medium was replenished and the resultant
supernatant, enriched with retroviruses, was collected at a 12-
hour interval twice, pooled, and then stored at 280uC. For
expressing RARRES1 under an inducible condition, the coding
region of RARRES1 was amplified by polymerase chain reactions
(PCR) and then cloned into pRetroX-Tight-Pur vector mediated
by BamHI and EcoRI restriction cleavages (New England Biolabs).
The resultant chimera (pRetroX-Tight-Pur-RARRES1) was af-
firmed to be mutation-free by DNA sequencing and then packed
into recombinant retrovirus. To ectopically express RARRES1 in
SUM159 cells, cells were maintained in Tet-free medium for at
least one passage and then infected by pRetroX-Tet-On Advanced
viruses followed by a drug selection. The G418 resistant cells were
subsequently infected with retrovirus encoding for pRetroX-Tight-
Pur-RARRES1 followed by a selection using two agents: G418
(500 mg/ml) and puromycin (2.5 mg/ml).
Downregulating CTCF by ShRNA
To knockdown CTCF in cells originally expressing high levels
of RARRES1, pSM2c-based retroviral vectors encoding either
scrambled or CTCF-specific shRNA (purchased from Open
Biosystems, Huntsville, AL) were transfected into cells to be tested
and followed by a selection with puromycin (2.5 mg/ml).
Subsequent experiments investigating the effect of CTCF silencing
on RARRES1 expression were carried out in cells derived from
3
rd passages after drug selection.
Assessing the Effect of Methylation on Promoter Activity
by in Vitro Methylation Followed by Luciferase Assays
The pGL3-Basic plasmid (Promega) reporting firefly luciferase
activity was integrated with various fragments amplified from the
RARRES1 promoter flanked with XhoI and HindIII (New England
Biolabs) restriction sites. The inserts in the chimera were proven to
be free-of-mutation by sequencing.
In vitro methylation was performed as described previously [16].
Briefly, 20 mg of chimera pGL3-Basic plasmid was cleaved by XhoI
and HindIII to retrieve the fragments encompassing RARRES1
sequences. The resultant insert moiety was divided into two equal
fractions and then each was either untreated (namely mock) or
treated with CpG methyltransferase SssI (New England Biolabs).
Epigenetic Suppression of RARRES1 in Breast Cancer
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36891After affirming the methylation status by a digestion with
methylation-sensitive restriction enzymes AciI (New England
Biolabs), inserts were ligated back into the pGL3-Basic, and then
introduced into 293 cells by using Lipofectamine 2000 (Invitrogen)
for luciferase assays. Furthermore, to serve as a control for
normalization, same cells were concordantly transfected with
Renilla luciferase vector. 48 hours later, cells were lysed and
luminescence was measured by Dual-Luciferase Reporter Assay
kit (Promega). The diminished ratio of firefly to renilla values thus
indicates a loss of promoter activity due to methylation.
ChIP
ChIP was carried out as described previously [17]. Briefly, cells
were fixed with 1% formaldehyde and then the resultant DNA-
protein complexes were sonicated followed by immunoprecipita-
tion using antibodies against H3K4me2 (Millipore), H3K27me3
(Diagenode), CTCF (Millipore) as well as the control normal
rabbit IgG (Millipore). After dissociating the DNA-protein
complexes, pulled-down DNA along with the input DNA (devoid
of antibody) were subject to qPCR analysis using primers
specifically interrogating different portions of the RARRES1
promoter. Folds of enrichment were calculated by ratio of signals
derived from ChIP DNA to those from the original input.
Western Blot Analysis
Cells were lysed in RIPA lysis buffer (Cell signaling) supple-
mented with protease inhibitor cocktail tablet (Roche). Approx-
imately 30–50 mg of proteins were resolved by 8–10% SDS-PAGE
and immunoblotted with antibodies against RARRES1 (R&D
Systems), CTCF (Millipore) and GAPDH (Cell Signaling)
respectively.
Invasion Assay
SUM159 variant stably transduced with pRetroX-Tight-Pur-
RARRES1 retroviruses were either treated with vehicle DMSO or
with Doxycycline (500 ng/mL) for 24 hours. Single-cell mixture
was obtained by trypsinization followed by suspension in the
reduced-serum medium (2% FBS), in the absence or presence of
Doxycycline. 1.25610
4 of the resultant cells were loaded to
Matrigel-coated invasion chambers (8 mm pore size; BD Biosci-
ences) to quantify the invasive property. Invasion process lasted 24
hours and was triggered by the medium that was placed outside of
the invasion chamber and supplemented with 10% FBS (either
without or with Doxycycline). The nonmotile cells located at the
top of the filter were sweep off by cotton swabs while the motile
cells transversed to the bottom of the filter were fixed with 70%
ethanol and stained with 0.1% crystal violet for cell counting. The
average number of migrated cells was quantified by the counts
cumulated from 10 representative areas captured by a microscope
with 200-fold magnification.
Immunohistochemical (IHC) Staining
Six sets of formalin-fixed paraffin-embedded sections, each
comprises primary tumor, adjacent benign, and metastatic lymph
node, were obtained from the Department of Pathology in our
institution. Clinical information was provided in the Table S2.
IHC staining was performed using the Histostain-Plus kit
(Invitrogen) according to the manufacturer’s instruction. Briefly,
paraffin sections were deparaffinized with xylene and rehydrated
in a series of descending concentrations of ethanol. Antigen
retrieving was carried out by immersing the slide in sodium citrate
buffer (pH 6.0) at 95uC for 15 minutes, while quenching the
endogenous peroxidase activity was achieved by incubating with
3% hydrogen peroxide. Non-specific epitopes were blocked prior
to incubating with specific antibody against RARRES1 (Sigma)
overnight at 4uC. On the next day, sections were incubated with
biotin-conjugated secondary antibody. The resultant immuno-
complexes were visualized by streptavidin-conjugated enzyme
along with DAB chromogen, counter-stained with hematoxylin
(Invitrogen), dehydrated, preserved and then viewed under a
BX45 Clinical Microscope (Olympus).
Reverse Transcription Followed by Quantitative PCR
Analysis (RT-qPCR)
Total RNA was extracted from cells by using Trizol (Invitrogen)
and 1.0 mg of which served as templates for generating the
complementary DNA (cDNA) mediated by SuperScript III reverse
transcriptase (Invitrogen). The resultant cDNA products were
mixed with RT
2 SYBR Green qPCR Master Mixes (Qiagen)
followed by quantitative PCR analysis on a 7500 fast real-time
PCR machine (Applied Biosystems). Gene expression was
normalized to the control transcript glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). Primer sequence used for qPCR is
available in the Table S3.
Survival Assay
SUM159 variant conditionally expressing RARRES1 was
treated with mock vehicle (DMSO) or with Doxycycline
(500 ng/mL) for 24 hours and then seeded in 96-well plates at a
density of 5,000 per well. On the next day, cells were either treated
with vehicle or with various concentrations of drugs (doxorubicin
or paclitaxel) for 2 days. Viability was quantified by using MTT
test (Sigma). Mock treated cells were set as 100% in relation to the
cells treated with drugs.
Statistical Analysis
The Student’s t test was conducted to analyze the significance of
variations between the control as well as experimental samples and
p,0.05 was regarded as significant.
Results
Methylation Occurring at the Region Upstream and Distal
from the RARRES1 Promoter Exerted Negligible Silencing
Effect in Primary Breast Tumors
To delineate how methylation at various regions flanking the
RARRES1 promoter interact with each other and with cofactors
for exerting ultimate silencing effect, we began to evaluate the
methylation occurring at sequences between 2664 and +420
(reference to TSS set as +1) in 18 pairs of primary breast tumors as
well as their matched benign tissues. In agreement with previous
findings [3], we observed that many tumors displayed higher
methylation levels than those obtained from the benign tissues
adjacent to the tumor cores (Figure 1A) with statistical significance
(p,0.001, Figure 1B). However, it is noteworthy that hypermethy-
lation solely occurred at the region far upstream from the TSS
(denoted as the distal region, spanning 2664,286; underlined
region in Figure 1A) while the downstream sequences (denoted as
the proximal region, flanking 285,+420) remained largely
unmethylated (Figure 1A). Since promoter methylation commonly
results in gene silencing, we next analyzed the correlation between
the levels of methylation and the degrees of RARRES1 expression.
Surprisingly enough, these two parameters were negligibly
correlated inferred by p value as being 0.147 (Figure 1C). To
substantiate this finding, IHC staining was performed to evaluate
RARRES1 in 6 independent cases. In a strong agreement, both
Epigenetic Suppression of RARRES1 in Breast Cancer
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36891geographic sections (tumor cores and benign tissues) expressed
comparable level of RARRES1 in all subjects examined (a
representative case is shown in Figure 1D).
Methylation of the Proximal Region of RARRES1 Promoter
was Necessary and Sufficient for Exerting Epigenetic
Repression Effect
To investigate the above paradoxical finding that hypermethy-
lation of RARRES1 at upstream distal sequences failed to exert
noticeable inhibitory effect on gene expression, we further
unraveled elsewhere regions that might possess intrinsic promoter
activity. As shown in Figure 2A, RARRES1 promoter and flanking
sequences were arbitrarily divided into a distal (denoted as D,
2664,273) and proximal (labeled as P, 291,+576) segments
(Figure 2A). Interestingly enough, region P, but not D, displayed
apparent promoter activity (,20 folds higher than that of basic
control) and was similar to the one from the combined region
(D+P) (Figure 2B). Our data thus indicated that region P alone is
sufficient to exhibit the vast majority of promoter activity. To
further investigate whether region P is susceptible to silence by
methylation, in vitro methylation assay was employed. Importantly,
methylation resulted in a dramatic decline of promoter activity
intrinsic to the P and D+P regions (Figure 2C). In contrast, the
same treatment negligibly lowered activity associated with region
D (Figure 2C). Assay reliance was inferred by the data showing
that mock treated (i.e. unmethylated) P and D+P regions still
displayed significantly higher promoter activity than the D region
(Figure 2C). Furthermore, promoter swap test was carried out by
cutting off the region linking D and P regions via NcoI followed by a
re-ligation of exchanged fragments. It was apparent that epigenetic
silencing was largely ascribed to methylation at the P region,
regardless in the context of methylated or unmethylated D (first 2
columns in Figure 2D). It is noteworthy to mention that
methylated D plus unmethylated P regions somewhat recapitulat-
Figure 1. Methylation occurring at sequences upstream and distal to the RARRES1 promoter exerted a negligible silencing effect in
primary breast tumors. (A) Primary breast tumors along with their matched adjacent benign tissues (total 18 cases examined) were analyzed for
DNA methylation by MassARRAY assay. Within the schema flanking RARRES1 promoter, each vertical line represented a single CpG site, while each
circle at the lower panel indicated various methylation level of a CpG unit that contained either single or multiple CpG sites. Sample names were
outlined at the left, while the average methylation levels occurring at the underlined region (2664,286) were denoted at the right. T, tumor core; N,
adjacent benign. (B) Dot plot revealed a significant gain of methylation at the underlined region in tumor cores compared to the ones in adjacent
benign tissues (p,0.001). (C) Scatter plot inferred expression of RARRES1 was unrelated to level of methylation at the same underlined sequences. (D)
Similar levels of RARRES1 expression between the breast tumor cores and the adjacent benign tissues were demonstrated by immunohistochemical
staining. A representative image was captured from case 1 (Table S2).
doi:10.1371/journal.pone.0036891.g001
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primary breast tumors (Figure 1A) and is in a strong agreement
with a lack of silencing effect (Figures 1C and 1D).
Methylation at the Proximal Region of RARRES1 Promoter
Rendered Silencing Effect in Breast Cancer Cell Lines
In order to seek a proof that methylated region P indeed
silenced RARRES1 expression, we correlated the methylation of
RARRES1 promoter with expression of transcript in not only
breast cancer cell lines classified into 3 different subtypes, i.e.
luminal, basal and mesenchymal [15,18], but also in the non-
neoplastic breast cell line (MCF10A) and primary normal human
mammary epithelial cells derived from different women (HMEC-
1, -2, and -3). As shown in Figure 3A, 5 out of 9 breast cancer cell
lines, i.e. SK-BR-3, BrCa-MZ-01, MCF7, SUM159, and BT-20
exhibited dramatic methylation (.80%), regardless of origins of
subtypes. SK-BR-7 and MDA-MB-231 cells showed moderate
methylation (30%–60%), while MDA-MB-453 and SUM149 as
well as the remaining nonmalignant breast epithelial cells
displayed low methylation (,10%). Despite that various breast
cancer cell lines displayed differential methylation levels at the
RARRES1 promoter (Figure 3A), they all retained similar degrees
of methylation at the constitutive hypermethylated locus know as
LINE-1 (Long Interspersed Nucleotide Element 1) serving as a
positive control for global methylation [19] (Figure S1). Never-
theless, the finding that all (100%) of nonmalignant breast
epithelial cells harbored negligible methylation (top 4 specimens
in Figure 3A) has supported our aforementioned notion that
methylation at sequences flanking RARRES1 promoter is highly
associated with breast carcinomas. Notably, methylation uniformly
spanned between regions D and P and displayed a pattern
strikingly distinct from that of primary tumors (compare Figure 3A
to Figure 1A). As cancer cell lines harboring elevated methylation
were predominantly originated from metastatic or effusion sites
(MCF7, MDA-MB-231, SK-BR-3 and SK-BR-7), it is reasoned
that metastastatic spread is correlated with methylation in region
P, despite that region D might have been methylated during the
preceding non-metastatic state. In supporting of this notion, all
cells (100%) displaying methylated region P concordantly
harbored methylated region D, suggesting the latter incidence
prelude the former. Alternatively, it might be reasonable to
speculate that the discrepancy of methylation patterns between the
cultured cell lines and the primary tumors might be ascribed to
either an outgrowth followed by a clonal enrichment (during cell
culture) of the sub-population that already acquired hypermethy-
lated region P or an induction of hypermethylation at region P
following in vitro cell culture. Nevertheless, the 5 cell lines
harboring remarkably elevated methylation (.80%), particularly
at region P, have dramatically lost RARRES1 transcript (Figure 3B)
and the reduction of expression correlated with the degrees of
methylation occurring at the P region-containing segments (D+P
or P) (p,0.001, Figure 3C). This finding agreed with the data
denoting methylation at region P, but unlikely region D, is
important for exerting epigenetic silencing effect (Figures 2C and
2D).
To affirm that DNA methylation indeed plays a role in silencing
of RARRES1, SUM159 and SK-BR-3 cells were treated with
epigenetic drugs (DAC or TSA or both) to partly reverse
epigenetic effect. DAC alone enabled restoration of RARRES1
expression in both cell lines originally silenced by methylation,
affirming that methylation was one of the critical causes rendering
silencing effect (Figure 3D). Of note, DAC synergized with TSA to
reactivate RARRES1 expression in SUM159 but not in SK-BR-3,
indicating that dual mechanisms (methylation in conjunction with
histone de-acetylation) played far critical roles in the former
whereas methylation alone was sufficient to exert a silencing
impact on the later cell line (Figure 3D).
Figure 2. Flanking sequences proximal to the RARRES1 promoter displayed a full promoter activity that can be suppressed by DNA
methylation. (A) Fragments (D, P and D+P) flanking the RARRES1 promoter were inserted to pGL3-Basic luciferase vector. (B) The resultant
constructs were transfected into 293T cells followed by luciferase assays for assessing promoter activity. While activity from pGL3-Basic was set as1 ,
the one from Renilla luciferase vector served as an internal control for normalization. (C) D, P, or D+P regions were either mockly treated
(Unmethylated, U) or methylated in vitro (M). The resultant fragments were further ligated to the luciferase vector backbone (pGL3-Basic) and subject
to luciferase analysis. Significance of difference (if p,0.01) was denoted by comparing unmethylated P and D+P to that of D (marked by *) or
methylated (M) to those of unmethylated counterparts (U) in samples P and D+P (denoted as #). (D) Various promoter activities were associated with
swap constructs (D and P), respectively derived from either the unmethylated (U) or methylated (M) state. The full activity was obtained from
unmethylated D(U)+P(U) set as 1, while * depicted a significant loss ascribed to methylation (p,0.01).
doi:10.1371/journal.pone.0036891.g002
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RARRES1 Promoter and thereby Regulated its Expression
Recently, multifunctional protein CTCF was reported to
epigenetically regulate expression of various tumor suppressors
including p16, BRCA1, Rb, PUMA and p53, possibly through
insulating chromatin boundaries such that prevented the spread of
upstream repressive chromatin [20–24]. ChIP-chip assay impli-
cated a putative CTCF binding motif existed in sequences flanking
283 bp to 239 bp upstream of TSS of RARRES1 [14] that
displayed sequence conservation with the one identified in the H19
promoter [25] (Figure S2A). We further reasoned that CTCF
occupancy perhaps acts as an insulator by prohibiting methylation
to further invade into region P and subsequently prevented
epigenetic silencing. Under this notion, binding to CTCF may be
influenced by surrounding histone markings. Herein, ChIP-qPCR
was carried out to analyze the occupancy of histone molecules
histone 3 lysine 4 dimethylation (H3K4me2) and histone 3 lysine
27 trimethylation (H3K27me3), two common histone variants
respectively indicative of transcriptionally-active and -repressed
chromatins [26]. In RARRES1-expressing (MCF10A) and -
silenced (SUM159) cells, we observed significantly elevated
occupancy of H3K4me2 in the former whereas increased
association of H3K27me3 in the latter, suggesting that a
pronounced chromatin remodeling has occurred in cells situated
at opposing expression states (Figure 4B). Interestingly, occupancy
of CTCF was predominantly correlated with coexistence of
H3K4me2 at the same promoter region (R4, a region flanking
sequences 2154,273 bp upstream of TSS) in MCF10A cells,
suggesting that this region might comprise a part of the ‘‘core’’
promoter element mediated by binding to CTCF and to
H3K4me2 (upper panels in Figure 4B and 4C). In support of
this notion, binding of CTCF and H3K4me2 at the RARRES1
promoter was similarly observed in RARRES1-expressing
SUM149 but not in silenced SK-BR-3 cells (data not shown). As
ChIP-qPCR indicated that the enrichment of CTCF binding
peaked at the R4 (Figure 4C), we theorize this region might be
involved in blocking methylation spread into region P exemplified
in the primary tumors (Figure 1A). This issue might be delineated
in the future studies, by assessing the effect of mutated the CTCF
core binding motif (flanking the RARRES1 promoter) on abrogat-
ing the ‘‘insulating’’ effect.
To further prove that the binding of CTCF played a key role in
regulating RARRES1 expression, shRNA was implemented to
down-regulate CTCF in MCF10A cells (Figure 5A). Interestingly,
knocking down CTCF not only resulted in a loss of its binding to
RARRES1 promoter (Figure 5B), but also reduced RARRES1
Figure 3. Methylation at the region proximal to the RARRES1 promoter rendered silencing effect in breast cancer cell lines. (A)
Degrees of methylation occurring at the sequence flanking the RARRES1 promoter (D+P) in normal breast epithelia and in cancer cell lines were
ranked in an ascending order. Names of breast cancer cell lines were color-coded as: blue for luminal (N=3), red for basal (N=3) and green for
mesenchymal (N=3). (B) Relative RARRES1 expression in the indicated cells was evaluated by RT-qPCR and compared to that of MCF10A set as 1. ND,
too low to be detected. (C) Scatter plot depicted an inverse correlation between RARRES1 expression and methylation occurring at either overall
(2664,+420, upper panel) or merely at the proximal region (285,+420, lower panel) in the aforementioned cell lines. (D) Treatment of SUM149 and
SK-BR-3 cells with epigenetic drugs reversed the silencing effect and re-stored expression inferred by increased transcripts assessed by RT-PCR.
doi:10.1371/journal.pone.0036891.g003
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supported that binding of CTCF to the RARRES1 promoter is
important for sustaining the promoter at the transcription-prone
state.
Re-expression of RARRES1 Impeded Cell Invasion and
Promoted Apoptosis
To investigate how silenced RARRES1 contributed to breast
neoplastic phenotypes, we engineered a Tet-On system in
SUM159 cells in which RARRES1 expression was originally
silenced but can be later induced upon the addition of doxycycline.
As shown in Figure 6A, both mRNA and protein levels of
RARRES1 increased drastically at 12 hours and peaked at 24
hours after the addition of doxycycline (Figure 6A). In concurrence
with previous reports examining various human cancers [2–4,6–
8,27], we observed that re-expression of RARRES1 not only
augmented cell death induced by cytotoxic agents Paclitaxel and
Doxorubicin (Figure 6B), but also impeded cell invasion (upper
panel of Figure 6C).
To gain clinical insight regarding how RARRES1 silencing
influences the dissemination of malignant cells, expression was
quantified between primary breast tumors and their corresponding
metastatic lymph nodes (total 6 cases examined, Tables S2 and S4)
by employing IHC staining using a RARRES1-specific antibody.
In agreement with our data that re-expression of RARRES1
inhibited cell invasion (upper panel, Figure 6C), RARRES1 was
generally down-regulated in metastatic lymph nodes compared to
those in the primary tumors (lower panel of Figure 6C) in all cases
examined (Table S4). Though metastasis property correlated with
a gain of tumor-initiating cells enriched in the ALDEFLUOR-
positive subfraction [28–31], RARRES1-restoration didn’t render
a loss of breast cancer-initiating cells (data not shown), excluding
the likelihood that RARRES1 regulates this activity. Taken
together, our data supported RARRES1 to be a tumor suppressor
gene in breast cancer and its downregulation, by DNA methyl-
ation, CTCF binding, or by histone remodeling, might favor
dissemination and survival of breast carcinoma. However, our
current data cannot delineate the chronological sequences
between these perturbations.
Discussion
Field cancerization was recently theorized [32], although
aberrant epigenetic silencing by methylation via a step-wise
manner hasn’t been extensively exemplified nor been correlated
with the cancer progression. For the first time, our preceding
report [9], as well as current study, depicted a likelihood that
tumor suppressor locus, RARRES1, was progressively methylated
prior to undergoing epigenetic silencing. Subsequently, downreg-
Figure 4. RARRES1 promoter was poised by active histone marking (H3K4me2) and co-occupied with CTCF in the expressing cells
(MCF10A), as opposed to the occupancy of repressive histone H3K27me3 with depleted CTCF binding in the non-expressing cells
(SUM159). (A) A schematic map revealed RARRES1 promoter as well as its flanking sequences (denoted as R1,R6) that were interrogated by ChIP-
qPCR assay. (B) RARRES1-expressing MCF10A and -silenced SUM159 cells were subjected to ChIP-qPCR analysis for assessing the abundance of
histone modifications. (C) CTCF occupancy was enriched in regions R4 in MCF10A but was absent in SUM159. Quality reliance is assured by a
negligible binding to normal IgG.
doi:10.1371/journal.pone.0036891.g004
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associated with advanced neoplastic states in various cancer types
[2–4,6–8,27] and in breast carcinomas (current report).
The nonmalignant breast epithelia MCF10A cells initially
harbored negligible methylation at sequences flanking RARRES1
promoter (Figure 3A), but later gained remarkable methylation
occurring at region D (or perhaps region P as well) after an
exposure to the tumor microenvironment provoked from breast
cancer-associated fibroblasts [9]. Gain of methylation was
demonstrated to be related to geographic distance that is inferred
from our data obtained from primary tumor cores versus the
matched adjacent benign tissues (Figure 1A) and is consistent with
the methylation spread theory [32,33]. Surprisingly enough, the
suppressing effect was not prominent until methylation was
extended to the neighboring element: region P (Figure 3A-C).
Despite that the upstream factors rendering aberrant methyl-
ation of region D was likely the tumor-environment via contacting
cancer-associated fibroblasts [9], the etiologic cause(s) rendering
region P methylation remains largely unknown. Presumably,
methylation at the region D acts as a catalyst to (A) recruit the
methylation machinery or histone modifications or (B) interact
between the two, or (C) synergize with additional effector
molecules like CTCF and H3K27me3. Notably, continuous
presence of methylated region D might be important for
expanding methylation into region P and leading to ultimate
silencing. The methylation profiles of regions D and P from the
Figure 5. Knocking down CTCF resulted in a significant loss of RARRES1 expression. (A) MCF10A cells were transduced with recombinant
viruses to express either control or CTCF shRNA, followed by a Western blot analysis to capture the expression of CTCF (upper) or GAPDH (lower,
served as a loading control). (B) Same cells were subjected to ChIP-qPCR analysis for assessing CTCF occupancy at regions R1-R6. (C) Knocking down
CTCF resulted in silencing of RARRES1 that can be inferred by RT-qPCR analysis. Significant loss of transcript was denoted by * if p,0.01.
doi:10.1371/journal.pone.0036891.g005
Figure 6. RARRES1 restoration impeded invasion and promoted cell death. (A) Re-expression of RARRES1 was induced in SUM159 variants
after been incubated with Doxycycline (Dox) for various durations. Expression level was assessed by RT-qPCR (upper) and by Western blot analysis
(lower), in comparison with an internal control GAPDH. (B) The same RARRES1-expressing SUM159 variant was either untreated or treated with Dox
for 24 hours. The resultant cells were then challenged with various doses of Paclitaxel and Doxorubicin for two days and the survival cells were
quantified by MTT assays. * inferred a significant change of cell viability (p,0.05). (C) Upper, a significant loss of invasive ability occurred in SUM159
variant re-expressing RARRES1. *, p,0.05. Lower, representative IHC images indicated a reduced RARRES1 expression in metastatic lymph nodes
compared to primary breast tumors of the same patient (cases 2 shown in Tables S2 and S4).
doi:10.1371/journal.pone.0036891.g006
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studied in this report revealed a ‘‘none-and-all’’ pattern but not an
‘‘either-or’’ fashion (Figure 3A).
Our data suggested a notion that ‘‘methylation seed’’ perhaps
existed in region D. This phenomenon agreed with published
findings that scattered CpG sites within a CpG island originally
acted as ‘‘catalysts’’ without necessarily exerting noticeable
silencing effect under normal circumstances, but later gained
methylation when cells progressed to malignant states. For
example, in gastric cancer cell lines, ‘‘methylated seeds’’ were
abnormally elevated that subsequently augmented methylation of
CpG island prior to conducting a permanent repression of
downstream genes [34,35]. Likewise, triggered by downregulated
SP1 transcription factor, random seeds of methylation acted as a
catalyst for the spread of methylation across the CpG island of the
Glutathione S-transferase promoter [36]. The seeds of DNA
methylation can also trigger histone deacetylation followed by
histone methylation, denoting a temporal relationship between
gene expression, DNA hypermethylation, and chromatin remod-
eling in cancer cells, particularly in prostate carcinomas [33].
The spread of methylation from the ‘‘seed’’ to the adjacent
sequences was worthwhile to mention. Methylation spread across
biparental origins was manifested in patients with Prader–Willi
syndrome-like features displaying hypo-pigmentation symptoms.
The maternal X-chromosome was not only inactivated by
methylation, but its aberrant methylation was also furthered into
the paternal chromosome 15 leading to the abnormal hyper-
methylation and silencing of downstream targets SNRPN and
OCA2 [37]. Similarly, selective ‘‘seed’’ methylation occurring at
the large tandem repeats becomes important for the subsequent
extension of the critically methylated region that resulted in stable
silencing of a locus namely FWA and thus prevented late flowering
in Arabidopsis thaliana [38]. On the other hand, demethylation of
both CpG and non-CpG methylation can be similarly expanded
and thus re-activate the myogenin transcript during muscle
differentiation [39], suggesting an epigenetic mechanism by
‘‘spreading’’ stretches of methylcytosines might be a common
occurrence in both CpG and non-CpG context.
Alternative mechanisms other than methylation ‘‘seed’’ are
worthy to be speculated. Instead of exerting direct impact,
methylated region D might indirectly interplay with other co-
factors or transcription factors or CpG-island shores that
subsequently augment local hypermethylation at region P. In
mouse methylome, CTCF binding was shown to be necessary and
sufficient to create a low-methylated regions and this effect was
partly ascribed to localized demethylation function associated with
CTCF [13]. In our study, by serving as a cis-acting element,
methlayted region D perhaps abrogated the occupancy of CTCF
at RARRES1 promoter (R4 region, 2154,272 upstream of TSS,
Figures 4A and 4C) and thus impaired CTCF’s ‘‘insulation’’ effect
as well as loss of de-methylation followed by a again of methylation
in the neighboring region P. Alternatively, methylated region D
might convey aberrant methylation at un-identified distal CpG
island shores [40] and this perturbation may subsequently
augment methylation of P-region, perhaps via a chromosome-
looping mechanism [41,42]. It is noteworthy to point out that the
influence of aberrantly methylated CpG island shores on
epigenetic silencing was recently denoted in human carcinomas.
By comparing colon tumors with patient-matched normal tissue,
Feinberg laboratory identified cancer-associated differentially
methylated regions were not only involved in transcriptional
silencing but were also located at CpG island shores rather than
the classical CpG islands or promoters [43].
Since CTCF appeared to be important for sustaining RARRES1
promoter at a transcription-prone state, it is of interest to speculate
how CTCF might become dysfunctional in RARRES1–silenced
cells. First of all, posttranslational modifications such as poly(ADP-
ribosyl)ation(PARylation)ofCTCFmightbe involvedinregulating
transcription activities as well as influencing DNA methylation of
target genes [20,44,45]. However, in current study, CTCF-180
(highly PARylated) and CTCF-130 (scantly PARylated) isoforms
[44] were similarly shown in RARRES1-expressing (MCF10A) and
–silenced (SUM159) cell lines, despite that CTCF-180 was
negligibly detected in both cell lines (Figure S3). This finding
excluded the likelihood that PARylation of CTCF plays a key role
influencing the binding to RARRES1 promoter in our study.
Alternatively, aberrant DNA methylation occurring at region D
mightabrogateCTCFbindingtoitscognatesequencewithinregion
P, as exemplified in the control of imprinted Igfr2/H19 loci [25].
Thus far, our findings cannot clearly evolve the mechanistic
sequence deciphering how CTCF binding influences methylation
and regulates expression of RARRES1. During the progression of
breast carcinomas, perhaps, the non-malignant stage would sustain
region D at the unmethylated state and thus facilitate the binding of
CTCFtoR4regionofRARRES1promoterbywhichmethylationat
regionPcanbeprevented.Latercarcinogenicinsultsorexposureto
breastcancer-associatedfibroblasts[9]mightaugmenthypermethy-
lation at region D and thus impaired its binding to transcription-
pronehistonemarkings,cofactors,aswellastoCTCF.Perhaps,loss
of CTCF occupancy abrogates demethylation activities intrinsically
associated with CTCF and thereby leads to methylation spread
moving towards region P.This perturbation thus results insilencing
of RARRES1 expression seen in the metastatic cultured cell lines
(Figure 3C) as well as in the primary lymph nodes manifesting the
advanced stages of breast neoplasm (Figure 6C).
Not only step-wise methylation flanking RARRES1 promoter
depicted a proof-of-principle, but also how it’s silencing impacts
malignant phenotypes is of great interest. Five lines tested in this
report(MCF7,MDA-MB-231,SK-BR-3,andSK-BR-7)harboring
silenced RARRES1 were virtually isolated from metastatic or
effusionsites,substantiating thenotionthatRARRES1isanegative
regulator for invasion and metastasis and that its silencing was a
common perturbation associated with lymph node metastasis
(Figure 6C). However, exceptional cases in cell lines harboring
prominent metastatic features but retained full RARRES1 transcript
might be ascribed to additional undiscovered perturbations (other
than RARRES1 suppression) that are also important for augment-
ing invasion and promoting metastasis properties.
Furthermore, the outcome ascribed to RARRES1 silencing
coincided with its clinical applications for treating human cancers.
For example, in conjunction with imatinib, all-trans retinoid acid
was used to treat gastrointestinal stromal tumors by impeding cell
proliferation and inducing apoptosis mediated through down-
regulated survivin as well as up-regulated Bax protein [46].
Moreover, the in vitro and in vivo effects of retinoids either alone or
in combination with cisplatin and 5-fluorouracil on tumor
development and metastasis of melanoma were assessed. Retinoids
not only showed significant anti-proliferation and anti-invasion
effects on murine melanoma B16-F10 cells, but also augmented the
antitumor activity of cisplatin in vivo [47].
Collectively, our findings delineated multiple molecular pertur-
bationsare responsible for epigenetic silencing ofRARRES1,inthe
light of the tumor microenvironmental effect, DNA methylation,
CTCF binding, as well as histone modifications. Identifying the
etiologic factor leading to methylation expansion (into region P) is
apparently important for developing therapeutic strategies. Future
treatment regimen by abrogating this trigger and thus blocking
Epigenetic Suppression of RARRES1 in Breast Cancer
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could potentially improve disease prognosis via hampering metas-
tasis, the common cause of death in a wide range of human
carcinomas including breast cancer.
Supporting Information
Figure S1 All breast cancer cell lines examined in this
report retained hypermethylation at the constitutive
methylated locus named LINE-1. To provide a methylation
control across cell lines studied in this report, we further
investigated the methylation degree of a globally methylated locus
know as LINE-1 (Long Interspersed Nucleotide Element 1) [1] by a
semi-quantitative assay known as combined bisulfite restriction
analysis (COBRA) [2]. DNA was extracted from the respective cell
lines and treated with sodium bisulfite followed by a PCR
amplification using the primers that do not contain CpG
dinucleotides so that the amplification step would not be
influenced by their original methylation status. The amplified
products were further subjected to restriction digestions to discern
methylated from the unmethylated DNA of interest. Briefly, the
combination of bisulfite treatment and PCR amplification results
in the sustenance of methylated cytosines thereby retains the
susceptible to BstUI digestion (inferred from the production of
restricted fragments). Under the same treatment, unmethylated
cytosines are converted to thymines and thus become resistant to
BstUI cleavage (denoted by a lack of restriction fragment). The
DNA template used in the positive control (denoted as Meth) was
the CpGenome Universal Methylated DNA (Millipore #S7821).
For generating a negative control (labeled as Un-Meth), the same
template was subjected to an extra step of PCR amplification prior
to bisulfite conversion such that methylated moieties can be
erased. Nevertheless, COBRA assay revealed that all cell lines
retained similar magnitudes of methylation at LINE-1 promoter,
disregard differential methylation degrees have occurred at
RARRES-1 promoter.
1. Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P
(2010) Somatic expression of LINE-1 elements in human
tissues. Nucleic Acids Res 38: 3909–3922.
2. Xiong Z, Laird PW (1997) COBRA: a sensitive and
quantitative DNA methylation assay. Nucleic Acids Res 25:
2532–2534.
(PPTX)
Figure S2 The putative CTCF binding motif flanking
RARRES1 promoter displays sequence homology with
the one in the B1 region of H19.A .The potential CTCF
binding motif located between 283 bp and 239 bp upstream of
transcriptional start site (TSS) of RARRES1 [3] was compared to
the H19 B1 CTCF binding segment [4]. Conserved bases were
revealed by the MAFFT method as previously described [5] and
shown in gray shades. B. Scheme of binding motifs flanking the
promoter region 2200 bp upstream of RARRES1 TSS. Boxes
denote locations of potential CTCF binding sites evolved from our
current study (denoted as Peng et al.) as well as from a previous
report [3] (labeled as Kim et al.). The various transcription factor
binding sites [6] flanking RARRES1 promoter were illustrated by
an on-line software http://www.cbrc.jp/research/db/
TFSEARCH.htm. Abbreviations for the transcription factors
are: Sp1: Specificity Protein 1; GATA1: GATA binding factor
1; GATA1/2, GATA binding factor 1 and GATA binding factor
2; E2F: Adenoviral E2 promoter binding factor; and MZF1:
myeloid zinc finger 1.
3. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI,
et al. (2007) Analysis of the vertebrate insulator protein CTCF-
binding sites in the human genome. Cell 128: 1231–1245.
4. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, et
al. (2000) CTCF mediates methylation-sensitive enhancer-
blocking activity at the H19/Igf2 locus. Nature 405: 486–489.
5. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a
novel method for rapid multiple sequence alignment based on
fast Fourier transform. Nucleic Acids Res 30: 3059–3066.
6. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel
AE, et al. (1998) Databases on transcriptional regulation:
TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26:
362–367.
(PPT)
Figure S3 CTCF isolated from RARRES1-expressing
(MCF10A) and –silenced cells (SUM159) displayed
similar degree of poly(ADP-ribosyl)ation (PARylation).
Detection of PARylation (denoted as PAR) by mmunoprecipita-
tion (IP) followed by western blotting was performed as previously
described [7]. In brief, semi-confluent culture of MCF10A or
SUM159 cells grown on 10-cm dishes were lyzed in 1000 ?l of IP
buffer (Pierce IP kit #26146) supplemented with protease inhibitor
cocktail (Roche). The lysate were incubated for 16 hours with
either anti-PAR-10H mouse monoclonal antibody (Enzo Life
Technology # ALX-804-220) or with anti-PAR rabbit polyclonal
antibody (EMD Millipore #528815) and then incubated respec-
tively with Protein A/G Agarose (Pierce #20422) or with HRP-
Protein A Agarose bead (BD#610438) for 2 hours. Immunopre-
cipitated products were analyzed by western blotting using anti-
CTCF polyclonal antibodies (Millipore #07-729). As both
RARRES1-expressing (MCF10A) and –silenced (SUM159) cells
harbor CTCF with similar levels of poly(ADP-ribosyl)ation
(PARylation), it is unlikely that a loss of CTCF binding in the
latter cell lines (Figure 4C) was ascribed to a decreased
PARylation.
7. Farrar D, Rai S, Chernukhin I, Jagodic M, Ito Y, et al. (2010)
Mutational analysis of the poly(ADP-ribosyl)ation sites of the
transcription factor CTCF provides an insight into the
mechanism of its regulation by poly(ADP-ribosyl)ation. Mol
Cell Biol 30: 1199–1216.
(PPTX)
Table S1 Clinicopathological information of breast tumors
assessed for DNA methylation by MassARRAY analysis. DCIS,
ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma; LCIS, lobular carcinoma in situ.
(DOCX)
Table S2 Clinicopathological information of breast tissues for
IHC staining.
(DOCX)
Table S3 DNA sequences of primers used in this study.
(DOCX)
Table S4 Summary of RARRES1 IHC (immunohistochemical)
staining.
(DOCX)
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